However, analysis of a cohort of patients with advanced melanoma treated with pembrolizumab or nivolumab (Hugo et al., 2016), both IgG4 mAbs directed against PD-1, with low predicted binding affinity to FcγRs, demonstrated no association between the CD16-V158F SNP and response rates in patients with high indel burden (Figure S5C). The gene discussed is FCGR3A; the disease is melanoma.